1
|
Ru S, Sun J, Zhou W, Wei D, Shi H, Liang Y, Wu J, Sun W, Chu L. Effects of traditional Chinese medicine in the treatment of patients with central serous chorioretinopathy: A systematic review and meta-analysis. PLoS One 2024; 19:e0304972. [PMID: 38905170 PMCID: PMC11192357 DOI: 10.1371/journal.pone.0304972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2023] [Accepted: 05/20/2024] [Indexed: 06/23/2024] Open
Abstract
Several studies have reported the efficacy of traditional Chinese medicine (TCM) for central serous chorioretinopathy (CSC), while some ophthalmologists are concerned that TCM may be a risk factor for CSC as some chinese herbs contain hormonal ingredients. This study aimed to evaluate the efficacy and safety of TCM in treating patients with CSC. Randomized controlled trials (RCTs) and observational studies of TCM for CSC were searched up to July 10, 2023 on the following biological databases without language and publication time restrictions: PubMed, Ovid Medline, Embase, Cochrane Library, The Chinese National Knowledge Infrastructure Database (CNKI), Technology Periodical Database (VIP), Wanfang, and Chinese Biomedical Literature Service System (SinoMed). Review Manager V.5.4.1 and Stata 14 software were used for data analysis. Finally, thirty-eight studies were finally included including 23 RCTs and 15 cohort studies. The meta-analysis showed that compared with the routine treatment alone, the combination of TCM can not only reduce the recurrence rate (OR = 0.29, 95% CI: 0.21,0.40; I2 = 0%) and central retinal thickness (CRT) (MD = - 35.63, 95% CI: - 45.96,-25.30; I2 = 89%) of CSC, but improve patients' best corrected visual acuity (BCVA) (SMD = 0.86, 95% CI: 0.62,1.11; I2 = 77%); additionally, it has no obvious side effects compared with routine treatment (OR = 0.72, 95% CI: 0.39,1.34; I2 = 10%). Overall, this study shows that the use of TCM does not increase the risk of CSC recurrence; on the contrary, the combination of TCM may reduce the recurrence of CSC and improve BCVA and CRT in patients with CSC compared with conventional treatment.
Collapse
Affiliation(s)
- Shuting Ru
- Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
- Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Jian Sun
- Department of Ophthalmology, Shanghai Pudong New Area Zhoupu Hospital, Shanghai, China
| | - Wanyu Zhou
- Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Dong Wei
- Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Hang Shi
- Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Yu Liang
- Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Jianguo Wu
- Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Wu Sun
- Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Liqun Chu
- Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
2
|
Liang Y, Zhang H, Li J, Wang X, Xie J, Li Y, Li J, Qian Y, Zhang H, Wang T, Tang H, Chen X. GLUT1 regulates the release of VEGF-A in the alveolar epithelium of lipopolysaccharide-induced acute lung injury. Cell Biol Int 2024; 48:510-520. [PMID: 38225684 DOI: 10.1002/cbin.12127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2023] [Revised: 11/20/2023] [Accepted: 01/01/2024] [Indexed: 01/17/2024]
Abstract
Acute lung injury (ALI) is a severe disease with high mortality and poor prognosis, characterized by excessive and uncontrolled inflammatory response. Vascular endothelial growth factor A (VEGF-A) contributes to the development and progression of ALI. The aim of this study was to evaluate the role of glucose transporter 1 (GLUT1) in alveolar epithelial VEGF-A production in lipopolysaccharide (LPS)-induced ALI. An ALI mouse model was induced by LPS oropharyngeal instillation. Mice were challenged with LPS and then treated with WZB117, a specific antagonist of GLUT1. For the vitro experiments, cultured A549 cells (airway epithelial cell line) were exposed to LPS, with or without the GLUT1 inhibitors WZB117 or BAY876. LPS significantly upregulated of GLUT1 and VEGF-A both in the lung from ALI mice and in cultured A549. In vivo, treatment with WZB117 not only markedly decreased LPS-induced pulmonary edema, injury, neutrophilia, as well as levels of interleukin (IL)-1β, IL-6 and tumor necrosis factor-α in bronchoalveolar lavage fluid (BALF), but also reduced VEGF-A production. Yet, the maximum tolerated concentration of WZB117 failed to suppress LPS-induced VEGF-A overexpression in vitro. While administration of BAY876 inhibited gene and protein expression as well as secretion of VEGF-A in response to LPS in A549. These results illustrated that GLUT1 upregulates VEGF-A production in alveolar epithelia from LPS-induced ALI, and inhibition of GLUT1 alleviates ALI.
Collapse
Affiliation(s)
- Yan Liang
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Hailing Zhang
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Jiahui Li
- Department of Pulmonary and Critical Care Medicine, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China
| | - Xilong Wang
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Jianpeng Xie
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Yijian Li
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Jiehong Li
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Yunyao Qian
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Haiyun Zhang
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Tao Wang
- State key Laboratory of Respiratory Diseases, Guangzhou Key Laboratory of Vascular Diseases, Guangzhou Institute of Respiratory Health, The Frist Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
| | - Haixiong Tang
- Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Xin Chen
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| |
Collapse
|
3
|
Zhao Y, Li J, Cao G, Zhao D, Li G, Zhang H, Yan M. Ethnic, Botanic, Phytochemistry and Pharmacology of the Acorus L. Genus: A Review. Molecules 2023; 28:7117. [PMID: 37894595 PMCID: PMC10609487 DOI: 10.3390/molecules28207117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 09/28/2023] [Accepted: 10/05/2023] [Indexed: 10/29/2023] Open
Abstract
The genus Acorus, a perennial monocotyledonous-class herb and part of the Acoraceae family, is widely distributed in the temperate and subtropical zones of the Northern and Southern Hemispheres. Acorus is rich in biological activities and can be used to treat various diseases of the nervous system, cardiovascular system, and digestive system, including Alzheimer's disease, depression, epilepsy, hyperlipidemia, and indigestion. Recently, it has been widely used to improve eutrophic water and control heavy-metal-polluted water. Thus far, only three species of Acorus have been reported in terms of chemical components and pharmacological activities. Previously published reviews have not further distinguished or comprehensively expounded the chemical components and pharmacological activities of Acorus plants. By carrying out a literature search, we collected documents closely related to Acorus published from 1956 to 2022. We then performed a comprehensive and systematic review of the genus Acorus from different perspectives, including botanical aspects, ethnic applications, phytochemistry aspects, and pharmacological aspects. Our aim was to provide a basis for further research and the development of new concepts.
Collapse
Affiliation(s)
- Yu Zhao
- Northeast Asia Research Institute, Changchun University of Chinese Medicine, Changchun 130117, China; (Y.Z.); (J.L.); (G.C.); (D.Z.); (G.L.)
- Jilin Provincial Science and Technology Innovation Center of Health Food of Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China
| | - Jia Li
- Northeast Asia Research Institute, Changchun University of Chinese Medicine, Changchun 130117, China; (Y.Z.); (J.L.); (G.C.); (D.Z.); (G.L.)
- Jilin Provincial Science and Technology Innovation Center of Health Food of Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China
| | - Guoshi Cao
- Northeast Asia Research Institute, Changchun University of Chinese Medicine, Changchun 130117, China; (Y.Z.); (J.L.); (G.C.); (D.Z.); (G.L.)
- Jilin Provincial Science and Technology Innovation Center of Health Food of Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China
| | - Daqing Zhao
- Northeast Asia Research Institute, Changchun University of Chinese Medicine, Changchun 130117, China; (Y.Z.); (J.L.); (G.C.); (D.Z.); (G.L.)
- Jilin Provincial Science and Technology Innovation Center of Health Food of Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China
| | - Guangzhe Li
- Northeast Asia Research Institute, Changchun University of Chinese Medicine, Changchun 130117, China; (Y.Z.); (J.L.); (G.C.); (D.Z.); (G.L.)
- Jilin Provincial Science and Technology Innovation Center of Health Food of Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China
| | - Hongyin Zhang
- Northeast Asia Research Institute, Changchun University of Chinese Medicine, Changchun 130117, China; (Y.Z.); (J.L.); (G.C.); (D.Z.); (G.L.)
- Jilin Provincial Science and Technology Innovation Center of Health Food of Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China
| | - Mingming Yan
- Northeast Asia Research Institute, Changchun University of Chinese Medicine, Changchun 130117, China; (Y.Z.); (J.L.); (G.C.); (D.Z.); (G.L.)
- Jilin Provincial Science and Technology Innovation Center of Health Food of Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China
| |
Collapse
|